Short answer
Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on September 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1). Board appointment of Mr. Ciongoli announced September 16, 2026.
Gossamer Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Board appointment of Mr. Ciongoli announced September 16, 2026
- Leadership addition may influence governance and strategic oversight
- Exhibit 99.1 contains the appointment announcement details
Item 5.02 · Departure/Election of Directors or Officers
- Gregory A. Ciongoli appointed Class III director through 2027 annual meeting and Audit Committee member
- Nasdaq-independent director with investment background at Baupost Group and Adiumentum Capital Management
- Annual compensation includes $40,000 board retainer and $7,500 Audit Committee retainer
- Ciongoli’s 2026 PIPE participation creates potential ownership alignment and financing-related insider ties
- PIPE-linked warrants potentially exercisable for approximately 200,869 common shares, subject to stockholder approval and FDA approval terms
Item EX-99.1 · Exhibit EX-99.1
- Greg Ciongoli appointed director effective September 16, 2026, adding public and private investment expertise
- Ciongoli joins the Audit Committee, strengthening financial oversight during seralutinib’s late-stage development
- Board appointment signals emphasis on value creation as Gossamer advances seralutinib toward potential FDA approval
- Ciongoli’s existing board roles include REGENXBIO, Zymeworks and Atara Biotherapeutics
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gossamer Bio, Inc. 8-K filings
Get the next GOSS 8-K as it lands
Follow GOSS for push alerts, or ask the research agent what this filing means.